The Case for Mandatory Newborn Screening for Severe Combined Immunodeficiency (SCID)

[1]  J. Puck,et al.  Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. , 2013, The Journal of allergy and clinical immunology.

[2]  A. Thrasher,et al.  Current progress on gene therapy for primary immunodeficiencies , 2013, Gene Therapy.

[3]  B. Kuehn.  After 50 years, newborn screening continues to yield public health gains. , 2013, JAMA.

[4]  L. Hammarström,et al.  Guidelines for newborn screening of primary immunodeficiency diseases , 2013, Current opinion in hematology.

[5]  H. Gaspar.  Gene therapy for ADA-SCID: defining the factors for successful outcome. , 2012, Blood.

[6]  K. Schwarz,et al.  Delayed-onset adenosine deaminase deficiency: strategies for an early diagnosis. , 2012, The Journal of allergy and clinical immunology.

[7]  A. Fischer,et al.  Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? , 2012, Blood.

[8]  U. Sack,et al.  Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR. , 2012, Blood.

[9]  T. Fleisher,et al.  The Wisconsin Approach to Newborn Screening for Severe Combined Immunodeficiency , 2012, Pediatrics.

[10]  W. Grossman,et al.  Newborn Screening for Severe Combined Immunodeficiency; The Wisconsin Experience (2008–2011) , 2012, Journal of Clinical Immunology.

[11]  S. Dixon,et al.  Putting a value on the avoidance of false positive results when screening for inherited metabolic disease in the newborn , 2012, Journal of Inherited Metabolic Disease.

[12]  J. Puck.  The case for newborn screening for severe combined immunodeficiency and related disorders , 2011, Annals of the New York Academy of Sciences.

[13]  L. Hammarström,et al.  Newborn screening for primary immunodeficiencies: beyond SCID and XLA , 2011, Annals of the New York Academy of Sciences.

[14]  J. Puck.  Neonatal screening for severe combined immunodeficiency , 2011, Current opinion in pediatrics.

[15]  Kee Chan,et al.  A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). , 2011, Molecular genetics and metabolism.

[16]  J. Verbsky,et al.  Screening newborns for primary T-cell immunodeficiencies: consensus and controversy , 2011, Expert review of clinical immunology.

[17]  Kathryn L. Parsley,et al.  Long-Term Persistence of a Polyclonal T Cell Repertoire After Gene Therapy for X-Linked Severe Combined Immunodeficiency , 2011, Science Translational Medicine.

[18]  Kathryn L. Parsley,et al.  Hematopoietic Stem Cell Gene Therapy for Adenosine Deaminase–Deficient Severe Combined Immunodeficiency Leads to Long-Term Immunological Recovery and Metabolic Correction , 2011, Science Translational Medicine.

[19]  Kathryn L. Parsley,et al.  Immunodeficiency: Long-term persistence of a polyclonal t cell repertoire after gene therapy for X-linked severe combined immunodeficiency , 2011 .

[20]  O. Ohara,et al.  Quantification of κ-deleting recombination excision circles in Guthrie cards for the identification of early B-cell maturation defects. , 2011, The Journal of allergy and clinical immunology.

[21]  M. van der Burg,et al.  Educational paper , 2011, European Journal of Pediatrics.

[22]  A. Gennery,et al.  Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. , 2011, Blood.

[23]  A. Fischer,et al.  Immune deficiencies , infection , and systemic immune disorders Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe : Entering a new century , do we do better ? , 2010 .

[24]  Frederic D. Bushman,et al.  Efficacy of gene therapy for X-linked severe combined immunodeficiency. , 2010, The New England journal of medicine.

[25]  L. Notarangelo,et al.  Guidelines for implementation of population-based newborn screening for severe combined immunodeficiency , 2010, Journal of Inherited Metabolic Disease.

[26]  R. Laessig,et al.  Implementing Routine Testing for Severe Combined Immunodeficiency within Wisconsin's Newborn Screening Program , 2010, Public health reports.

[27]  L. Prosser,et al.  Systematic Evidence Review of Newborn Screening and Treatment of Severe Combined Immunodeficiency , 2010, Pediatrics.

[28]  A. Fischer,et al.  Gene therapy for primary immunodeficiencies. , 2010, Immunology and allergy clinics of North America.

[29]  Alessandro Aiuti,et al.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2009, The New England journal of medicine.

[30]  R. Laessig,et al.  Statewide newborn screening for severe T-cell lymphopenia. , 2009, JAMA.

[31]  H. Kanegane,et al.  Identification of severe combined immunodeficiency by T-cell receptor excision circles quantification using neonatal guthrie cards. , 2009, The Journal of pediatrics.

[32]  R. Laessig,et al.  Development of a routine newborn screening protocol for severe combined immunodeficiency. , 2009, The Journal of allergy and clinical immunology.

[33]  A. Fischer,et al.  Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. , 2009, Blood.

[34]  L. Notarangelo,et al.  Omenn syndrome: inflammation in leaky severe combined immunodeficiency. , 2008, The Journal of allergy and clinical immunology.

[35]  T. Cole,et al.  Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. , 2008, Blood.

[36]  A. Andermann,et al.  Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. , 2008, Bulletin of the World Health Organization.

[37]  J. Puck.  Neonatal screening for severe combined immune deficiency , 2007, Current opinion in allergy and clinical immunology.

[38]  L. Notarangelo,et al.  Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. , 2007, The Journal of allergy and clinical immunology.

[39]  F. Miedema,et al.  Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency. , 2006, Blood.

[40]  A. Thrasher,et al.  Gene therapy for severe combined immunodeficiencies , 2005, Expert opinion on biological therapy.

[41]  J. Puck,et al.  Development of population-based newborn screening for severe combined immunodeficiency. , 2005, The Journal of allergy and clinical immunology.

[42]  A. Fischer,et al.  Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99 , 2003, The Lancet.

[43]  J. Puck,et al.  Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. , 2002, Blood.

[44]  M. Cowan,et al.  Cutaneous manifestations of maternal engraftment in patients with severe combined immunodeficiency: a clinicopathologic study , 2001, Bone Marrow Transplantation.

[45]  J. Roberts,et al.  Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. , 1999, The New England journal of medicine.

[46]  A. Fischer,et al.  European experience of bone-marrow transplantation for severe combined immunodeficiency , 1990, The Lancet.

[47]  A. Gennery,et al.  The expanding clinical and immunological spectrum of severe combined immunodeficiency , 2011 .

[48]  Ja Wilson,et al.  Principles and practice of screening for disease , 1968 .